Table 2.

Outcomes by diagnosis.

Endpoint	Diagnosis	Start of drug	6 Months eplerenone	12 Months eplerenone	P for time	P for diagnosis
PINP (μg/mL)	TGA	52.2 ± 24.9	55.7 ± 24.2	47.6 ± 10.8	0.21	0.12
	TOF	43.7 ± 14.2	38.0 ± 14.4	36.5 ± 11.6
PIIINP (μg/mL)	TGA	4.8 ± 1.5	4.8 ± 1.5	4.5 ± 1.1	0.46	0.15
	TOF	4.7 ± 2.5	4.1 ± 1.6	4.4 ± 2.0
G3 (ng/mL)	TGA	11.1 ± 1.5	11.7 ± 2.3	11.1 ± 2.1	0.21	0.73
	TOF	10.7 (9.5, 12.2)	12.6 ± 3.9	11.4 ± 2.4
6MWD (feet)	TGA	1688.2 ± 254.8	1650.4 ± 219.7	1711.2 ± 253.5	0.23	0.35
	TOF	1575.1 ± 181.3	1542.3 ± 242.7	1641.5 ± 268.6
SF-36 total	TGA	78.5 ± 13.7	82.8 (77.1, 85.3)	79.2 ± 8.8	0.44	0.68
	TOF	88.2 (79.2, 91.2)	87.8 (70.2, 89.0)	85.6 (75.0, 88.6)
SF-36 physical	TGA	82.5 ± 14.8	83.0 ± 11.1	83.5 ± 8.5	0.37	0.61
	TOF	95.0 (65.0, 97.5)	96.3 (67.5, 100.0)	95.0 (72.5, 95.0)
Serum creatinine (mg/dL)	TGA	1.0 ± 0.2	0.9 (0.9, 1.1)	1.0 ± 0.2	0.52	0.49
	TOF	0.9 ± 0.3	0.9 (0.7, 1.2)	0.9 ± 0.1
Serum potassium (mEq/L)	TGA	4.5 ± 0.5	4.4 ± 0.5	4.5 ± 0.4	0.48	0.29
	TOF	4.4 ± 0.5	4.5 (4.2, 5.2)	4.3 ± 0.4

PINP indicates procollagen 1 N-terminal peptide; PIIINP, procollagen 3 N-terminal peptide; G3, galectin-3; 6MWD, 6-minute walk distance; SF-36, Short Form 36; TGA, transposition of the great arteries; TOF, tetralogy of Fallot.